Clinical Trials Browser

Active not recruiting × NIH × ibrutinib × Clear all

NCT01886872 2026-03-19

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 3 Active not recruiting

547 enrolled 19 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02159755 2026-03-19

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

Phase 1 Active not recruiting

Lymphoma, Mantle-Cell

NCT01841723 2026-03-18

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT03701282 2026-03-18

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02160015 2026-03-17

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02048813 2025-11-28

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3 Active not recruiting

529 enrolled 12 charts 2 FDA

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01955499 2025-11-10

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1 Active not recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01849263 2025-09-10

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

Phase 2 Active not recruiting

41 enrolled 12 charts

Lymphoma, Follicular

NCT02581930 2025-09-08

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Phase 2 Active not recruiting

18 enrolled 10 charts

Melanoma

NCT03220022 2025-07-18

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Phase 1 Active not recruiting

Lymphoma, AIDS-Related

NCT01500733 2024-09-19

PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Active not recruiting

86 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02514083 2024-09-19

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

Phase 2 Active not recruiting

29 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell